神経変性疾患市場

Neurodegenerative Disease Market

神経変性疾患または神経変性とは、神経細胞の進行性の損傷または消耗を指す。神経変性疾患は、意思決定や最終的な記憶喪失といった能力の喪失を引き起こす。神経変性疾患は、パーキンソン病、ハンチントン病、筋... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Future Market Insights フューチャーマーケットインサイツ	2022年6月28日	US$5,000 シングルユーザライセンスライセンス・価格情報注文方法はこちら	250	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

神経変性疾患または神経変性とは、神経細胞の進行性の損傷または消耗を指す。神経変性疾患は、意思決定や最終的な記憶喪失といった能力の喪失を引き起こす。神経変性疾患は、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病といった様々な疾患を含む、より広い意味での疾患である。これらは、「神経変性」という病態の下で最も一般的に発生する疾患である。神経変性は遺伝的要因によって引き起こされることもあるが、その割合はごくわずかである。神経変性の主な原因は、脳内に有毒なタンパク質物質が沈着すること、あるいは脳内に存在するミトコンドリアの機能喪失や機能不全である。一般に、患者は1つまたは複数の神経変性疾患の混合症状を示す。現在のところ、この病態を治療する薬はないが、症状を最小限に抑える特定の薬剤が市販されている（例えば、アルツハイマー病にはドネペジルとメマンチン、パーキンソン病にはL-ドパ、ALSにはリルゾール）。

神経変性疾患市場：促進要因と阻害要因

神経変性疾患市場は、神経疾患の診断と治療の両面における医療技術の継続的な進歩により、神経変性治療薬の需要が高まっているため、拡大が見込まれている。神経変性市場の成長を促進する主な要因として、高齢化人口の増加、ひいては神経疾患の発生率の増加が挙げられる。先進国では、医師の意識の高まりが市場の成長を支えている。発展途上国、特にアジア太平洋諸国は人口が多いため、今後数年間で市場の大幅な成長が見込まれる。神経変性疾患の多様な性質のため、完全な治療手段がないことが、世界レベルでの神経変性疾患市場の妨げになる可能性がある。

神経変性疾患市場セグメンテーション

神経変性疾患市場は薬剤クラス、適応症、地域によって分類される。

薬剤クラスに基づいて、世界の神経変性疾患市場は以下のように区分される：

NMDA
SSRI
ドーパミン阻害薬
適応症に基づくと、世界の神経変性疾患市場は以下のように区分される：

パーキンソン病
ハンチントン病
筋萎縮性側索硬化症
アルツハイマー病
神経変性疾患市場概要

神経変性疾患市場は、主に神経疾患の症例数増加により大きな成長が見込まれている。同市場は、新しいタイプの薬剤の上市により、今後数年間で躍進が見込まれる。アルツハイマー病市場では、GABA受容体モジュレーター、抗アミロイド・プロテイン剤、ニコチンおよびコリン作動性受容体アゴニストなどの薬剤が市場成長に影響を与えると予想されるが、パーキンソン病市場では、ドーパミン受容体アゴニストおよび再取り込み阻害剤、グルタミン酸受容体モジュレーター、アドレナリン作動性拮抗薬およびアデノシン拮抗薬などの薬剤の発売が市場を牽引するとみられる。今後数年間は、大手企業の特許切れによる新規参入が予想される。

神経変性市場：地域別展望

地理的地域によって、世界の神経変性疾患市場は7つの主要地域に区分される：北米、南米、東欧、西欧、アジア太平洋、日本、中東・アフリカ。神経変性疾患の世界市場は年平均成長率約5%で成長すると予想される。アジア太平洋地域は人口が多いため、予測期間中に最も高い成長が見込まれる。

神経変性疾患市場主要プレイヤー

世界の神経変性疾患市場における主要プレイヤーには、Novartis、Pfizer、Merck Serono、Biogen Idec、TEVA Pharmaceuticals Industries、UCB、Boehringer Ingelheim、Sanofi S.A.、GlaxoSmithKlineなどが挙げられる。大手製薬企業は、今後数年間は特許切れによる競争に直面するだろう。

この調査レポートは、市場の包括的な評価を提示し、思慮深い洞察、事実、過去のデータ、統計的に裏付けられ業界で検証された市場データを含んでいます。また、適切な仮定と方法論を用いた予測も含まれています。この調査レポートは、市場セグメント、地域、タイプ、技術、用途などのカテゴリー別に分析と情報を提供しています。

本レポートでは、以下の項目について網羅的に分析しています：

市場セグメント
市場ダイナミクス
市場規模
需要と供給
現在のトレンド/問題/課題
競合・参入企業
テクノロジー
バリューチェーン
地域分析

北米（米国、カナダ）
中南米（メキシコ、ブラジル）
西ヨーロッパ（ドイツ、イタリア、フランス、英国、スペイン、その他の西ヨーロッパ地域）
東欧（ロシア）
アジア太平洋（中国、インド、ASEAN、オーストラリア、ニュージーランド）
日本
中東・アフリカ（GCC、南アフリカ）
本レポートは、業界アナリストによる生の情報、質的・量的評価、業界専門家およびバリューチェーン全体にわたる業界参加者からのインプットをまとめたものです。本レポートでは、親市場の動向、マクロ経済指標、支配要因について、セグメントごとの市場魅力とともに詳細に分析しています。また、様々な市場要因が市場セグメントや地域に与える定性的な影響もマッピングしています。

レポートのハイライト

親市場の詳細な概要
業界における市場ダイナミクスの変化
詳細な市場セグメンテーション
過去、現在、そして予測される市場規模（数量ベース、金額ベース
最近の業界動向と発展
競合他社の状況
主要企業の戦略と提供製品
潜在的かつニッチなセグメント、有望な成長を示す地理的地域
市場パフォーマンスに関する中立的な視点
市場関係者が市場での足跡を維持・強化するための必携情報
注 - レポートに記載されている事実、意見、分析はすべて各アナリストのものです。これらは必ずしもFuture Market Insightsの正式な立場や見解を反映するものではありません。

ページTOPに戻る

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication, 2022-2032

        5.3.1. Alzheimer’s Disease

        5.3.2. Motor Neuron Diseases

        5.3.3. Parkinson’s Disease

        5.3.4. Huntington’s Disease

        5.3.5. Multiple Sclerosis

        5.3.6. Others

    5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022-2032

Deep-dive segmentation will be available in the sample on request

6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        6.3.1. Cholinesterase Inhibitors

        6.3.2. Dopamine Inhibitors

        6.3.3. MAO-B Inhibitors

        6.3.4. Catechol-O-methyltransferase Inhibitors

        6.3.5. Anticholinergics

        6.3.6. Antipsychotic Drugs

        6.3.7. Dopamine Antagonists

        6.3.8. Others

    6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

Deep-dive segmentation will be available in the sample on request

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032

        7.3.1. Oral Drugs

        7.3.2. Parenteral Drugs

        7.3.3. Topical Drugs

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032

Deep-dive segmentation will be available in the sample on request

8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

        8.3.4. Drug Stores

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

Deep-dive segmentation will be available in the sample on request

9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. East Asia

        9.3.5. South Asia & Pacific

        9.3.6. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. U.K.

            10.2.1.2. Canada

        10.2.2. By Disease Indication

        10.2.3. By Drug Class

        10.2.4. By Route of Administration

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Indication

        10.3.3. By Drug Class

        10.3.4. By Route of Administration

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Disease Indication

        11.2.3. By Drug Class

        11.2.4. By Route of Administration

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Indication

        11.3.3. By Drug Class

        11.3.4. By Route of Administration

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Disease Indication

        12.2.3. By Drug Class

        12.2.4. By Route of Administration

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Indication

        12.3.3. By Drug Class

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Disease Indication

        13.2.3. By Drug Class

        13.2.4. By Route of Administration

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Indication

        13.3.3. By Drug Class

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Thailand

            14.2.1.3. Indonesia

            14.2.1.4. Malaysia

            14.2.1.5. Singapore

            14.2.1.6. Australia

            14.2.1.7. New Zealand

            14.2.1.8. Rest of South Asia & Pacific

        14.2.2. By Disease Indication

        14.2.3. By Drug Class

        14.2.4. By Route of Administration

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Disease Indication

        14.3.3. By Drug Class

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Disease Indication

        15.2.3. By Drug Class

        15.2.4. By Route of Administration

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Disease Indication

        15.3.3. By Drug Class

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. U.K.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2021

            16.1.2.1. By Disease Indication

            16.1.2.2. By Drug Class

            16.1.2.3. By Route of Administration

            16.1.2.4. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2021

            16.2.2.1. By Disease Indication

            16.2.2.2. By Drug Class

            16.2.2.3. By Route of Administration

            16.2.2.4. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2021

            16.3.2.1. By Disease Indication

            16.3.2.2. By Drug Class

            16.3.2.3. By Route of Administration

            16.3.2.4. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2021

            16.4.2.1. By Disease Indication

            16.4.2.2. By Drug Class

            16.4.2.3. By Route of Administration

            16.4.2.4. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2021

            16.5.2.1. By Disease Indication

            16.5.2.2. By Drug Class

            16.5.2.3. By Route of Administration

            16.5.2.4. By Distribution Channel

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2021

            16.6.2.1. By Disease Indication

            16.6.2.2. By Drug Class

            16.6.2.3. By Route of Administration

            16.6.2.4. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2021

            16.7.2.1. By Disease Indication

            16.7.2.2. By Drug Class

            16.7.2.3. By Route of Administration

            16.7.2.4. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2021

            16.8.2.1. By Disease Indication

            16.8.2.2. By Drug Class

            16.8.2.3. By Route of Administration

            16.8.2.4. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2021

            16.9.2.1. By Disease Indication

            16.9.2.2. By Drug Class

            16.9.2.3. By Route of Administration

            16.9.2.4. By Distribution Channel

    16.10. China

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2021

            16.10.2.1. By Disease Indication

            16.10.2.2. By Drug Class

            16.10.2.3. By Route of Administration

            16.10.2.4. By Distribution Channel

    16.11. Japan

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2021

            16.11.2.1. By Disease Indication

            16.11.2.2. By Drug Class

            16.11.2.3. By Route of Administration

            16.11.2.4. By Distribution Channel

    16.12. South Korea

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2021

            16.12.2.1. By Disease Indication

            16.12.2.2. By Drug Class

            16.12.2.3. By Route of Administration

            16.12.2.4. By Distribution Channel

    16.13. India

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2021

            16.13.2.1. By Disease Indication

            16.13.2.2. By Drug Class

            16.13.2.3. By Route of Administration

            16.13.2.4. By Distribution Channel

    16.14. Thailand

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2021

            16.14.2.1. By Disease Indication

            16.14.2.2. By Drug Class

            16.14.2.3. By Route of Administration

            16.14.2.4. By Distribution Channel

    16.15. Indonesia

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2021

            16.15.2.1. By Disease Indication

            16.15.2.2. By Drug Class

            16.15.2.3. By Route of Administration

            16.15.2.4. By Distribution Channel

    16.16. Malaysia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2021

            16.16.2.1. By Disease Indication

            16.16.2.2. By Drug Class

            16.16.2.3. By Route of Administration

            16.16.2.4. By Distribution Channel

    16.17. Singapore

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2021

            16.17.2.1. By Disease Indication

            16.17.2.2. By Drug Class

            16.17.2.3. By Route of Administration

            16.17.2.4. By Distribution Channel

    16.18. Australia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2021

            16.18.2.1. By Disease Indication

            16.18.2.2. By Drug Class

            16.18.2.3. By Route of Administration

            16.18.2.4. By Distribution Channel

    16.19. New Zealand

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2021

            16.19.2.1. By Disease Indication

            16.19.2.2. By Drug Class

            16.19.2.3. By Route of Administration

            16.19.2.4. By Distribution Channel

    16.20. GCC Countries

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2021

            16.20.2.1. By Disease Indication

            16.20.2.2. By Drug Class

            16.20.2.3. By Route of Administration

            16.20.2.4. By Distribution Channel

    16.21. South Africa

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2021

            16.21.2.1. By Disease Indication

            16.21.2.2. By Drug Class

            16.21.2.3. By Route of Administration

            16.21.2.4. By Distribution Channel

    16.22. Israel

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2021

            16.22.2.1. By Disease Indication

            16.22.2.2. By Drug Class

            16.22.2.3. By Route of Administration

            16.22.2.4. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Disease Indication

        17.3.3. By Drug Class

        17.3.4. By Route of Administration

        17.3.5. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. F. Hoffmann-La Roche Ltd

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Novartis AG

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Biogen

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Teva Pharmaceuticals Industries Ltd.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Eisai Co., Ltd.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Sanofi

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Merck KGaA

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. UCB S.A

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Boehringer Ingelheim International GmbH

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. GlaxoSmithKline plc

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. Neuro-Hitech, Inc.

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. BioVision Inc

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

        18.1.13. Aquinnah Pharmaceuticals

            18.1.13.1. Overview

            18.1.13.2. Product Portfolio

            18.1.13.3. Profitability by Market Segments

            18.1.13.4. Sales Footprint

            18.1.13.5. Strategy Overview

                18.1.13.5.1. Marketing Strategy

        18.1.14. ADDEX THERAPEUTICS

            18.1.14.1. Overview

            18.1.14.2. Product Portfolio

            18.1.14.3. Profitability by Market Segments

            18.1.14.4. Sales Footprint

            18.1.14.5. Strategy Overview

                18.1.14.5.1. Marketing Strategy

        18.1.15. Cellcentric

            18.1.15.1. Overview

            18.1.15.2. Product Portfolio

            18.1.15.3. Profitability by Market Segments

            18.1.15.4. Sales Footprint

            18.1.15.5. Strategy Overview

                18.1.15.5.1. Marketing Strategy

        18.1.16. Mission Therapeutics

            18.1.16.1. Overview

            18.1.16.2. Product Portfolio

            18.1.16.3. Profitability by Market Segments

            18.1.16.4. Sales Footprint

            18.1.16.5. Strategy Overview

                18.1.16.5.1. Marketing Strategy

        18.1.17. CogRx

            18.1.17.1. Overview

            18.1.17.2. Product Portfolio

            18.1.17.3. Profitability by Market Segments

            18.1.17.4. Sales Footprint

            18.1.17.5. Strategy Overview

                18.1.17.5.1. Marketing Strategy

        18.1.18. Denali Therapeutics Inc

            18.1.18.1. Overview

            18.1.18.2. Product Portfolio

            18.1.18.3. Profitability by Market Segments

            18.1.18.4. Sales Footprint

            18.1.18.5. Strategy Overview

                18.1.18.5.1. Marketing Strategy

        18.1.19. Psyadon Pharmaceuticals, Inc.

            18.1.19.1. Overview

            18.1.19.2. Product Portfolio

            18.1.19.3. Profitability by Market Segments

            18.1.19.4. Sales Footprint

            18.1.19.5. Strategy Overview

                18.1.19.5.1. Marketing Strategy

        18.1.20. Cipla Inc.

            18.1.20.1. Overview

            18.1.20.2. Product Portfolio

            18.1.20.3. Profitability by Market Segments

            18.1.20.4. Sales Footprint

            18.1.20.5. Strategy Overview

                18.1.20.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

ページTOPに戻る

Table of Contents

Summary

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Neurodegeneration is a broader term which comprises of different disease namely Parkinson’s disease, Huntington disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. These are the most commonly occurring diseases under the condition “Neurodegeneration”. Neurodegeneration can be caused due to genetic factor but the proportion is minimal. Major cause of neurodegeneration could be deposition of toxic protein substance in the brain or loss of functionality/improper functioning of mitochondria present in brain. Patients generally show mixture of symptoms for one or more neurodegenerative disease. Currently there is no cure for this condition however specific drugs are present in the market to minimize the symptoms (for example: donepezil and memantine for Alzheimer’s disease, L-dopa for Parkinson’s, riluzole for ALS).

Neurodegenerative Disease Market: Drivers & Restraints

Neurodegenerative market is expected to dwell due to continuous advancement in medical technology both for the diagnosis and the treatment of neurological disorders have raised the demand of neurodegenerative drugs. Ageing population is increasing which in turn is leading to increase in the incidence of neurological disorders are some major factors driving the growth of neurodegenerative market. Growing awareness amongst the physicians is helping the market to dwell in developed countries. Developing countries especially Asia Pacific countries, where due to large population the market growth is expected to be significant in the upcoming years. Lack of complete curative treatment measures primarily because of the manifold nature of the disease could possibly hamper the market of neurodegenerative disease market at the global level.

Neurodegenerative Market: Segmentation

Neurodegenerative market is classified on the basis of Drug class, indications and geography.

Based on Drug class, the global Neurodegenerative disease market is segmented into the following:

NMDA
SSRIs
Dopamine Inhibitors
Based on Indications, the global Neurodegenerative disease market is segmented into the following:

Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease
Neurodegenerative Disease Market: Overview

Neurodegenerative disease market is expected to grow at a significant pace mainly due to increasing cases of neurological disorders. The market is expected to witness advancement in the upcoming years due to launch of new type of drugs. In the Alzheimer’s market, drugs like GABA receptor modulators, anti-amyloid protein agents and nicotinic and cholinergic receptor agonists are expected to influence the market growth however in the Parkinson’s disease market will be driven due to launch of drugs like dopamine receptor agonists and reuptake inhibitors, glutamate receptor modulators, and adrenergic and adenosine antagonists. New players are expected to enter the market in the forecast years due to patent protection loss for major players.

Neurodegenerative Market: Region-wise Outlook

Depending on geographic regions, global neurodegenerative disease market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. Global market for neurodegenerative disease is expected to grow by a CAGR of around 5%. Asia Pacific is expected to witness the highest growth due to large population base over the forecast years.

Neurodegenerative Market: Key Players

Some of the key market players in global Neurodegenerative market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA Pharmaceuticals Industries, UCB, Boehringer Ingelheim, Sanofi S.A., GlaxoSmithKline to name a few. Major players will face competition in the upcoming years due to patent protection loss.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Rest of Western Europe)
Eastern Europe (Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

Future Market Insights社の医療・製薬・メディカルデバイス分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Future Market Insights社はどのような調査会社ですか?

Future Market Insights（FMI）は世界の広範な地域および産業を対象にした調査レポートを出版しています。弊社ウェブサイトに掲載のないタイトルも全てお取り扱い可能ですので... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

神経変性疾患市場

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療）の最新刊レポート

Future Market Insights社の医療・製薬・メディカルデバイス分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Future Market Insights社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?